EGFR and pancreatic neoplasm: In the present study, in view of these preliminary findings we examined the biological and biochemical effects of AS104 on pancreatic cancer cells notoriously resistant to gemcitabine treatment (17,18) and showing aberrant expression of EGFR and HER-2 tyrosine kinases, respectively.